Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete

Shattuck Labs, Inc.

2022-Q3 EPS reported -$1.81 revenue$262,000

Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.
Cash and investments $185.1M as of Sep 30, 2022, down from $268.8M at Dec 31, 2021; cash runway into H2 2024.
Completed enrollment in Phase 1 monotherapy dose-escalation of SL-172154 in platinum-resistant ovarian cancer; final data expected midyear 2023.
First patient dosed in Phase 1B combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer; initial data expected midyear 2023.
R&D expenses $18.9M (up 25% YoY); G&A $6.6M (up 53% YoY, including $1.4M litigation settlement).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Shattuck Labs, Inc. reported the quarter ended September 30, 2022 results: net income ($0.58) per basic and diluted share, EPS $0.58 per basic and diluted share.

Period: the quarter ended September 30, 2022
Net income: ($0.58) per basic and diluted share
EPS: $0.58 per basic and diluted share
Result: reported results

Exact text from the filing

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-22-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.